A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Clinical trial NCT02065336 · TERMINATED
Trial details
- NCT number
- NCT02065336
- Sponsor
- Arrowhead Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-01
- Primary completion
- 2017-01-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.